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Abstract
Background: Chronic fatigue syndrome (CFS) is defined by self-reported symptoms. There are no diagnostic
signs or laboratory markers, and the pathophysiology remains inchoate. In part, difficulties identifying and
replicating biomarkers and elucidating the pathophysiology reflect the heterogeneous nature of the syndromic
illness CFS. We conducted this analysis of people from defined metropolitan, urban, and rural populations to
replicate our earlier empirical delineation of medically unexplained chronic fatigue and CFS into discrete
endophenotypes. Both the earlier and current analyses utilized quantitative measures of functional impairment
and symptoms as well as laboratory data. This study and the earlier one enrolled participants from defined
populations and measured the internal milieu, which differentiates them from studies of clinic referrals that
examine only clinical phenotypes.
Methods: This analysis evaluated 386 women identified in a population-based survey of chronic fatigue and
unwellness in metropolitan, urban, and rural populations of the state of Georgia, USA. We used variables
previously demonstrated to effectively delineate endophenotypes in an attempt to replicate identification of these
endophenotypes. Latent class analyses were used to derive the classes, and these were compared and contrasted
to those described in the previous study based in Wichita, Kansas.
Results: We identified five classes in the best fit analysis. Participants in Class 1 (25%) were polysymptomatic,
with sleep problems and depressed mood. Class 2 (24%) was also polysymptomatic, with insomnia and
depression, but participants were also obese with associated metabolic strain. Class 3 (20%) had more selective
symptoms but was equally obese with metabolic strain. Class 4 (20%) and Class 5 (11%) consisted of nonfatigued,
less symptomatic individuals, Class 4 being older and Class 5 younger. The classes were generally validated by
independent variables. People with CFS fell equally into Classes 1 and 2. Similarities to the Wichita findings
included the same four main defining variables of obesity, sleep problems, depression, and the multiplicity of
symptoms. Four out of five classes were similar across both studies.
Conclusion: These data support the hypothesis that chronic medically unexplained fatigue is heterogeneous and
can be delineated into discrete endophenotypes that can be replicated. The data do not support the current
perception that CFS represents a unique homogeneous disease and suggests broader criteria may be more
explanatory. This replication suggests that delineation of endophenotypes of CFS and associated ill health may be
necessary in order to better understand etiology and provide more patient-focused treatments.
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Introduction
Chronic fatigue syndrome (CFS) is a common, debilitat-
ing illness whose hallmark symptoms involve fatigue and
fatigability [1-5]. CFS has no diagnostic clinical signs or
laboratory markers and is diagnosed based on self-
reported symptoms and the ruling out of medical and psy-
chiatric conditions that present similarly. There are several
published definitions of CFS [1,4,5] that have proved use-
ful in standardizing research subjects but lack empirical
support [6,7]. Several studies have described the heteroge-
neity of CFS [6,8-11], but they recruited patients from
clinical practices and relied on clinical and demographic
information rather than physiological data. These studies
have failed to identify consistent subgroups. Despite its
prevalence and documented heterogeneity, systematic
approaches to identify the endophenotypes comprising
CFS have not been adopted.
We recently reported a more comprehensive approach to
delineate the heterogeneity of medically unexplained
chronic fatigue in 159 women from a population-based
sample in Wichita, Kansas, USA [12,13]. That study used
principal components analysis to screen about 500 clini-
cal, demographic, and laboratory measurements acquired
from the 159 women during a two-day in-hospital case-
control study and found that 38 variables accounted for
the majority of the variance. Latent class analysis of these
38 variables identified four classes as the best fit model.
Classes containing the most severely fatigued women
were differentiated by sympathetic nervous system and
endocrine activity, polysomnographic measures of sleep,
mood disturbance, and multiplicity of symptoms.
Women in Class 1 (32%) were unwell and obese with lab-
oratory findings characteristic of metabolic strain. They
had polysomnographic changes of hypnoea and were
depressed and polysymptomatic. Women in Class 2
(28%) were obese but well. Those in Class 3 (26%) were
unwell, polysymptomatic, and depressed, but had rela-
tively normal body mass indices and normal biological
markers. Finally, Class 4 (16%) comprised relatively well,
non-obese women who were more symptomatic than
Class 2.
We validated these latent classes against various inde-
pendent measures, including severity, disability, gene
expression profiles, and single nucleotide polymorphisms
[13-15]. This is in accord with results from another study
of 55 patients recruited from specialist care that has
reported that quantitative gene expression analysis can
differentiate seven CFS subgroups [16]. However, only
gene expression was used to delineate the subgroups.
The objective of the current analysis was to replicate our
previous comprehensive delineation approach with data
collected during a survey of people from a different popu-
lation, identified from metropolitan, urban, and rural
populations of Georgia [17]. Although there were some
differences in the measures used, we hypothesized that we
would confirm the heterogeneity of medically unex-
plained chronic fatigue, and that the same measures
would differentiate similar subgroups as those defined in
the Wichita population-based study.
Methods
This study adhered to human experimentation guidelines
of the U.S. Department of Health and Human Services
and the Helsinki Declaration. The CDC Institutional
Review Board approved the study protocol. All partici-
pants were volunteers who gave informed consent.
Study participants
This study was part of a larger effort to evaluate the occur-
rence of, and risk factors for, CFS and unwellness in the
18- to 59-year-old population of the state of Georgia. Fig-
ure 1 summarizes the sample, and details are available
elsewhere [17]. Briefly, between September 2004 and July
2005, we used random digit dialing to conduct a house-
hold screening interview with a household informant in
three Georgia populations (metropolitan, urban, and
rural). A household informant described demographics
and health status of household members ages 18 to 59.
That initial interview enumerated 19,807 adult residents
and screened for unwellness among household members
for whom at least one CFS symptom was reported
(fatigue, impaired cognition, un-refreshing sleep, muscle
or joint pain). Well residents had none of these symptoms
for  ≥ one month. The screening interview identified
10,834 (55%) well people; 5,122 (26%) people who were
unwell for at least a month but not fatigued; and 3,851
(19%) people who were unwell and fatigued for at least a
month. We then conducted detailed telephone interviews
with all those identified as unwell with fatigue, a random
selection of those who were unwell but without fatigue,
and a random sample of well people (see Figure 1). Based
on their responses to the detailed telephone interview, we
classified participants as CFS-like if they met criteria of the
1994 CFS case definition [5]; as chronically unwell if they
exhibited some but not all CFS symptoms; and as well if
they reported no such symptoms. Finally, we invited all
469 people classified as CFS-like; 641 well people
(matched to the CFS-like people by sex, race/ethnicity,
age, and geographic stratum); and a similar number (n =
505) of randomly selected unwell people for a one-day
clinical evaluation. Overall, 48.5% completed the clinical
evaluation.
Clinical evaluation and illness classification
To identify medical conditions considered exclusionary
for CFS [5,7], the clinical evaluation included a standard-
ized past medical history, a review of systems, a standard-Population Health Metrics 2009, 7:17 http://www.pophealthmetrics.com/content/7/1/17
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ized physical examination, and routine laboratory testing
of blood and urine [5,7]. To identify psychiatric condi-
tions considered exclusionary for CFS, licensed and specif-
ically trained psychiatric interviewers administered the
Structured Clinical Interview for DSM-IV (SCID) [18].
Exclusionary psychiatric disorders included current mel-
ancholic major depression, any psychotic condition,
bipolar affective disorder, active substance abuse/depend-
ence, anorexia or bulimia nervosa [5,7]. Subjects with cur-
rent non-melancholic major depressive episode or a past
history of major depressive disorder were not excluded.
The study identified exclusionary medical or psychiatric
conditions in 280 (36%) of those evaluated clinically.
They were excluded from further analyses, as were two
others with incomplete data, leaving a total sample of 501
subjects.
We also diagnosed CFS based on the clinical evaluation
according to criteria of the 1994 case definition [5] and as
recommended by the International CFS Study Group [7],
which is standard in CDC studies of CFS. Thus, we evalu-
ated functional impairment by means of the Medical Out-
comes Short-Form Health Survey (SF-36) [19]. We used
the Multidimensional Fatigue Inventory (MFI-20) [20] to
measure characteristics of fatigue, and we utilized the
CDC CFS Symptom Inventory to document occurrence,
frequency, and severity of the defining symptoms [21].
Subjects who had ≥ four case-defining symptoms, who
exceeded the Symptom Inventory cut-off score, and who
met CFS cut-off scores on the SF-36 and the MFI-20 were
considered to have CFS (n = 113 participants). Those who
met at least one, but not all CFS criteria, comprised the ISF
group (n = 264), and those who met none of the cut-off
criteria comprised the Well group (n = 124). In consider-
ation of inadequate sample size for detecting the hetero-
geneity in both sexes, and for replication of the Wichita
study (which only studied women), we opted to only
study women. This left 386 women in the analysis for this
paper.
Metropolitan, Urban, and Rural Georgia Study Populations Figure 1
Metropolitan, Urban, and Rural Georgia Study Populations.
Screening Telephone Interviews
(19,807 persons enumerated)
Well (n = 10,834) Unwell (n = 8,973)
Random selection (n = 3,116) Not Fatigued (n = 5,122) Fatigued (n = 3,851)
Random selection (n = 2,134)
Detailed Telephone Interview (CATI)
(n = 5,623)
Telephone classification: Well (n = 1,782) Chronically Unwell (n = 1,763) CFS-like (n = 469)
79% response
71% response
(n = 2,438)
67% response (n = 1,429) 56% response (n = 1,756)
Exclusionary conditions (n = 1,609)
Completed clinic (n = 783)
62% response (n = 292)
Random selection (n = 505)
53% response (n = 268)
(n = 223 frequency matched to CFS-like
by age, race, sex, residential area)
Exclusionary conditions (n=280); 
missing data (n = 2))
Well (n = 124) ISF (n = 264) CFS (n = 113) Clinic Classification:Population Health Metrics 2009, 7:17 http://www.pophealthmetrics.com/content/7/1/17
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Independent variables used to delineate the subgroups
Although many of the 38 variables used in the Wichita
study were the same (see Table 1), some, such as noctur-
nal polysomnography, were not measured in the Georgia
study. In all, 26 clinical and laboratory variables were the
same or very similar to the 38 variables used in the
Wichita study [13]. When a variable was not available, we
used proxy measures to estimate the effect of the missing
variable (see Table 1). Cortisol index was the sum of four
serum cortisol concentrations taken regularly over 24
hours minus the baseline concentration.
Independent variables used to validate the subgroups
In order to externally validate the subgroups, we used the
Short-Form Health Survey measure of functioning (SF-36)
[19] and the Multidimensional Fatigue Inventory [20],
neither of which had been used to define the classes.
Statistical analysis
We used Latent GOLD® (LatentGOLD 4.1.3, Statistical
Innovations, MA, USA) software to perform latent class
analyses (LCA) on all variables and all subjects. Non-cat-
egorical variables were dichotomized by median split, and
we filled missing (null) values (0.4% missing data values)
with an intermediate categorical value. LCA is a statistical
method for finding subtypes of similar subjects (latent
classes) using multiple, defining, and categorical varia-
bles. LCA searches for an optimal class assignment for
each subject so that most of the variation in the entire
dataset can be explained by the subject's class assignment
alone. LCA posits the existence of statistically uncorre-
lated measurements within each of the discovered classes.
One therefore seeks measurements that most fully define
Table 1: Defining variables used in the Wichita and Georgia 
studies
Wichita Georgia
Unrefreshing sleep Unrefreshing sleep
Sleep problems Sleep problems
Post-exertional fatigue Post-exertional fatigue
Muscle pain Muscle pain
Joint pain Joint pain
Severe headache Headache
Concentration Concentration
Photophobia Photophobia
Sore throat Sore throat
Shortness of breath Shortness of breath
Stomach or abdominal pain Stomach or abdominal pain
Fever Fever
Nausea Nausea
Depression (Zung score) Depression (Zung score)
Sleepiness (Epworth score) Sleepiness (Epworth score)
O2saturation
Sleep resp. disturbance index
Sleep-total time
Sleep-total arousals
Sleep-HR variability Heart rate at rest
Sleep REM latency
Age Age
Body mass index Body mass index
Neck circumference Neck circumference
High sensitivity CRP High sensitivity CRP
Serum insulin Serum insulin
Free T3
Progesterone
Free testosterone
24 hours Urinary free cortisol Cortisol index
Hemoglobin Hemoglobin
Bilirubin Bilirubin
AST AST
IL-6
IL-1b
Igf-1
Tilt BP_5min_stand_index Systolic blood pressure
Table 1: Defining variables used in the Wichita and Georgia 
studies (Continued)Population Health Metrics 2009, 7:17 http://www.pophealthmetrics.com/content/7/1/17
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Table 2: Latent classes obtained from a five-class solution
Class Attributes Class-1 Class-2 Class-3 Class-4 Class-5 Wald p-Value
Number (%) of subjects 97 (25) 92 (24) 77 (20) 76 (20) 44 (11)
Stomach problems (%) 57 46 25 12 18 39.2 0.000
Concentration difficulty 33 53 5 0 0 29.1 0.000
Fever 22 28 6 7 16 17.6 0.002
Headache 84 79 53 46 77 33.8 0.000
Joint pain 61 71 34 30 0 34.0 0.000
Muscle pain 81 87 44 46 34 46.9 0.000
Nausea 37 44 10 5 18 31.2 0.000
Photophobia 44 63 14 8 0 51.6 0.000
Shortness of breath 22 47 8 0 4 32.0 0.000
Sore throat 52 58 13 13 36 45.0 0.000
Unusual fatigue 70 86 32 8 11 89.6 0.000
Unrefreshing sleep 98 97 45 41 14 63.9 0.000
Sleep problems 94 97 49 46 29 68.4 0.000
Sleepiness (Epworth score) 10 10 5 6 5 58.6 0.000
Depression (Zung score) 53 56 43 39 35 92.4 0.000
Age (years) 42 44 48 51 38 37.6 0.000
BMI (kg/m2) 24 32 32 24 22 85.6 0.000
Neck circumference (cm) 33 37 37 34 32 72.6 0.000
High sensitivity CRP (mg/dL) 0.10 0.42 0.51 0.1 0.08 72.4 0.000
Serum insulin (units?) 3.9 8.9 8.4 3.9 3.7 79.4 0.000
Cortisol index 1.9 1.5 2.0 1.7 2.2 11.1 0.026
Serum bilirubin 0.4 0.4 0.4 0.5 0.4 14.5 0.006
Serum AST 15 16 15 18 15 15.9 0.003
Hemoglobin 13.0 13.4 13.1 13.3 12.6 20.6 0.000
Heart rate (bpm) 68 68 72 64 64 9.8 0.043
Systolic blood pressure 110 124 126 120 108 55.2 0.000
Figures show (%) of total number in a class endorsing a symptom, median score on self-rating scales, or for biological markers, the median value for 
the respective class. The variables shown in the table are those significantly contributing to the class solution according to the Wald statistic. BMI = 
Body Mass Index. CRP = C reactive protein. AST = Aspartate transaminase.Population Health Metrics 2009, 7:17 http://www.pophealthmetrics.com/content/7/1/17
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the variability in the dataset, but are uncorrelated with
each other. LCA and other clustering techniques seek to
find loci in the multidimensional space of measurements
(clinical and biological) where subjects cluster together.
The subjects that are close to each other belong to the
same class. Finding the locus for each class requires fitting
one parameter for each dimension (measurement), and
specifying a locus in an n-dimensional space requiring n
parameters. To determine the optimal number of latent
classes, we utilized the Akaike Information Criterion
(with 3 as penalizing factor) (AIC3). AIC3 is defined by
the following equation:
where L is the likelihood and npar is the number of esti-
mated parameters.
Recent results [22,23] suggest AIC3 is a better criterion
than Bayesian or AIC for LCA models. We utilized AIC3
for the Wichita study and also utilize it here. The optimal
number of classes is determined through locating a mini-
mum in the value of AIC3 for solutions with different
numbers of clusters. To validate the different classes, we
compared independent variables across the empirically
defined classes using Kruskal-Wallis or Mann-Whitney U
tests for interval variables. Variables tested for validity
included the Short-Form Health Survey (SF-36) and the
Multidimensional Fatigue Inventory. A final test of valida-
tion was used to compare the empirically defined classes
against a standardized application of impairment, fatigue,
and symptom criteria of the 1994 CFS case definition [24]
as recommended by the International CFS Study Group
[7] and the screening criteria of "unwell and not fatigued"
and "well."
Results
The AIC3 results for the four-, five-, and six-class solutions
were respectively 13,856, 13,844, and 13,846. A five-class
solution was statistically most significant, as the AIC3 was
the lowest for this solution (13,844), and we therefore
only show these data (four- and six-class solutions not
shown).
Table 2 shows the five classes and associated data relating
the variables that contributed significantly to the model as
indicated by the Wald statistic. Class 1 (25%) captured ill
subjects with many symptoms, prominent fatigue, sleep
problems, and depression, but no aberrant biological
AIC L npar 32 3 =− + log *
Table 3: Descriptive data, disability, and fatigue scores (as medians) for each class defined in the five-class solution
Descriptive Data Class-1 Class-2 Class-3 Class-4 Class-5
Number in class 97 92 77 76 44
Age (years) 42 44 48 51 38
CFS illness duration (years) 4.3 2.8 5.1 N/A N/A
Disability (SF-36)
Physical Functioning 80 70 85 93 100
Mental Health 60 60 84 88 92
Social Functioning 75 56 100 100 100
Fatigue (MFI)
General Fatigue 16 16 12 8 7
Physical Fatigue 12 14 11 7 6
Mental Fatigue 1 3 1 3 875
Reduced Activity 9 1 1 766
Reduced Motivation 1 1 1 2 866
SF-36 = Short-Form Health Survey
MFI = Multidimensional Fatigue InventoryPopulation Health Metrics 2009, 7:17 http://www.pophealthmetrics.com/content/7/1/17
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markers (including body mass index) characterized this
group. Class 2 (24%) similarly captured ill subjects who
reported prominent, widespread symptoms, insomnia,
and depression. However, these subjects had an associ-
ated metabolic syndrome (elevated insulin and inflam-
matory markers) and were obese. Class 3 (20%) included
less ill subjects with fewer symptoms but similarly obese
individuals with elevated serum insulin and inflamma-
tory markers. Class 4 (20%) and Class 5 (11%) primarily
included well individuals of normal weight. Class 5
included the youngest individuals and Class 4 the oldest.
As in the Wichita study, the four-class solution (data not
shown) (AIC3 = 13,856) divided the sample along the
dimension of obesity, resulting in two obese and two nor-
mal-weight classes. A secondary division on the basis of
symptomatology shaped the final four classes such that
Class 1 (27% of subjects) constituted a group of well sub-
jects with normal BMI (median BMI = 23; median age =
45). Class 2 (25%) contained symptomatic and depressed
subjects, with prominent sleep problems and normal BMI
(median BMI = 24, median age = 42) but without abnor-
mal biological markers. Class 3 subjects (25%) were obese
(median BMI = 33; median age = 44), with the highest lev-
els of symptoms, prominent depression, and poor sleep.
In addition, these subjects had low cortisol levels and
showed signs of obesity-associated metabolic strain,
including higher levels of insulin and inflammatory mark-
ers. Class 4 (23%) consisted of obese older individuals
(medium BMI = 31; median age = 48) with some sign of
metabolic strain (e.g., raised insulin and inflammatory
markers), but who were otherwise well.
Validation against independent variables not included in 
the model
The median values on the variables originally omitted
from deriving optimal class solutions are shown for each
of the five classes in Table 3. With all five classes included
in the analysis, nonparametric ANOVA produced highly
significant overall tests indicative of substantial between-
class differences for all variables (see Table 4). We used
Mann-Whitney U follow-up tests for fatigue and disability
scores to compare each of the three ill classes against the
two well classes (Classes 4 and 5). This confirmed signifi-
cant differences across all the dimensions of disability and
fatigue between Classes 1 and 2 and the well Classes 4 and
5 (all P  values < 0.001). Comparisons among the less
symptomatic but still ill Class 3 and both of the well
classes still produced highly significant differences for
physical functioning, and for general, physical, and men-
tal fatigue (all P values < 0.008). Similarly, there were sig-
nificant differences in activity and motivation (all P values
< 0.009). Reported levels of mental and social functioning
were substantively different only between Class 3 and
Class 5 (P values < 0.003).
Significant between-class differences also distinguished
the three ill/fatigued classes in all disability and fatigue
categories (Table 4). Follow-up tests showed no signifi-
cant differences between Classes 1 and 2 on the SF-36
dimensions [19] of mental functioning and the Multidi-
mensional Fatigue Inventory subscales [20] of general
Table 4: Independence of all five classes and the three classes 
defining ill/fatigued subjects
All Classes 3 Ill Classes
Disability (SF-36) χ2 P χ2 P
Physical functioning 129.2 0.000 26.8 0.000
Mental health 133.5 0.000 48.0 0.000
Social functioning 159.1 0.000 57.1 0.000
Fatigue (MFI)
General fatigue 177.8 0.000 47.1 0.000
Physical fatigue 149.2 0.000 22.7 0.000
Mental fatigue 164.4 0.000 64.5 0.000
Activity reduction 80.1 0.000 17.6 0.000
Motivation reduction 117.4 0.000 30.2 0.000
SF-36 = Short-Form Health Survey
MFI = Multidimensional Fatigue Inventory
Table 5: Distribution of cases identified by the CDC research criteria for unexplained fatigue (CFS and unwell/not fatigued) and well 
controls across the empirically derived five classes: N (%)
Class 1
(n = 97)
Class 2
(n = 92)
Class 3
(n = 77)
Class 4
(n = 76)
Class 5
(n = 44)
CFS (n = 92) 41 (44) 47(51) 3(3) 1(1) 0
unwell not fatigued (n = 201) 53 (26) 43(21) 56(28) 32(16) 17(8)
well (n = 93) 3 (3) 2(2) 18 (19) 43 (46) 27 (29)Population Health Metrics 2009, 7:17 http://www.pophealthmetrics.com/content/7/1/17
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fatigue, mental fatigue, and reduction in motivation (all P
values > 0.05). However, Class 2 reported significantly
lower physical (P < 0.000) and social functioning (P <
0.01) and higher levels of physical fatigue (P < 0.007) and
activity reduction (P < 0.009) than Class 1. Comparisons
of SF-36 and fatigue scores between Classes 1 and 3
revealed no statistically significant difference in SF-36
physical functioning, but differences on the dimensions
of mental and social functioning (both P values < 0.000).
Additional differences between these two classes were evi-
dent on general fatigue, mental fatigue, and reduction in
motivation (all P values < 0.000), and to a lesser degree
for physical fatigue (P < 0.01) and activity reduction (P <
0.04). Comparisons between the most symptomatic Class
2 and the least symptomatic Class 3 of the ill classes were
all significantly different at the P < 0.000 level.
Table 5 shows the distribution of criterion-based diag-
noses: CFS, unwell but not fatigued, and well individuals.
People diagnosed as CFS fell almost exclusively into
Classes 1 and 2. Those who were unwell but not fatigued
were fairly evenly spread across all classes, while the well
were most commonly found in Classes 4 and 5, with a
small minority in Class 3.
Table 6 compares and contrasts the four class solutions
across the two studies in Georgia and Wichita. There was
a close similarity in the content of all four classes. Table 7
compares and contrasts the five class solutions across the
same two studies. Four out of the five classes were very
similar in their content.
Discussion
This analysis supported the heterogeneity of unexplained
chronic fatigue in a population-derived sample. The most
statistically rigorous latent classes were five in number,
although the four-class solution was equally interpretable.
The five-class solution provided three ill classes and two
relatively well classes. The ill classes were differentiated by
multiple symptoms, obesity, metabolic strain, depressed
mood, and sleep problems. The four-class solution pro-
vided two well and two unwell groups, with differentiat-
ing variables being the same as for the five-class solution.
The validation of the classes was supported by the signifi-
cant differences across classes in the independent varia-
bles, such as fatigue subscale scores and disability. CFS
was divided across two subgroups, while the unwell but
not fatigued group was more heterogeneous, represented
in all five classes. As expected, well people primarily made
up Classes 4 and 5.
Comparison with the Wichita study
How do these results compare with the Wichita classes?
First, the main variables that differentiated the classes
Table 6: Comparisons of four class solutions across the two studies
Summarized content of classes Georgia Class (% cases) Wichita Class (% cases)
Not obese and well 1 (27) 4 (16)
Not obese, polysymptomatic, depressed, insomnia 2 (25) 3 (26)
Obese, metabolic strain, polysymptomatic, insomnia, depressed 3 (25) 1 (32)
Obese, metabolic strain, but relatively well 4 (20) 2 (28)
Table 7: Comparisons of five class solutions across the two studies
Summarized content of classes Georgia Class (% cases) Wichita Class (% cases)
Not obese, polysymptomatic, depressed, insomnia 1 (25) 5 (13)
Obese, metabolic strain, polysymptomatic, depressed, insomnia 2 (24) 1 (28)
Obese, metabolic strain, fewer symptoms of pain and insomnia, not depressed 3 (20) 2 (23)
Not obese, fewer symptoms of pain and insomnia, not depressed 4 (20) 4 (17)
Well, bar headache, young 5 (11)
Obese, metabolic strain, fewer symptoms of pain and insomnia, depressed 3 (19)Population Health Metrics 2009, 7:17 http://www.pophealthmetrics.com/content/7/1/17
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were similar: obesity, metabolic strain, multiplicity of
physical symptoms, sleep problems, and depression. Sec-
ondly, the four-class solutions were very similar across the
two studies, and four out of the five class solutions were
also similar.
The dissimilarities include empirically describing a five-
class solution in Georgia compared to a four-class solu-
tion in Wichita. The absence of measures of sympathetic
nervous system arousal, such as nocturnal heart-rate vari-
ability and polysomnography, used in the Wichita study,
may explain the lack of further similarities between the
two samples. Similarly, the inability to differentiate a sixth
class, similar to that reported in the Wichita sample, was
probably related to the absence of the sex steroid hor-
mone assays in the Georgian sample because the sixth
class was defined primarily by being post-menopausal
[12]. The SF-36 physical function subscale scores were
higher than we expected, but the scores were similar to
those of the relevant subjects from the Wichita study and
probably reflect the sample being derived from the popu-
lation rather than a clinic. Previous studies of CFS have
also used a previous version (version 1 rather than 2) of
the SF-36 scale, with a slightly different stem question,
which also may have affected the data.
Comparisons with other studies of heterogeneity
The multiplicity of symptoms in some classes supports the
two previous studies differentiating CFS on the basis of a
minority having features of somatisation [8,9]. The
importance of depression reflects the differentiation
found on the basis of mood disturbance in the largest
study of heterogeneity using the Swedish twin registry,
which found two main subgroups, one of which was dif-
ferentiated primarily by comorbid mood disorders [25].
Kerr and colleagues' finding of seven subgroups was based
on secondary and tertiary care samples and was deter-
mined by gene expression alone [16]. Apart from the
Wichita study, for which this is a replication, no other
study has defined subgroups using both clinical and labo-
ratory data, so no other comparisons are possible.
Limitations of this replication
The most important limitation was the absence of some
variables that had been used in the Wichita study. These
primarily included objective measures of sleep, such as
polysomnography, and autonomic nervous system tests
such as heart rate variability. Our employment of proxy
variables was unsuccessful because they rarely played a
differentiating role in the analyses. We were careful to oth-
erwise keep the variables and their preliminary process-
ing, as well as the analyses, the same. In view of the
discrepancy in important variables, it is remarkable that
so many similarities were found. The addition of other
variables, which neither study measured, such as actigra-
phy and other psychiatric comorbidities (e.g., anxiety),
might have further enhanced the differentiation of classes
[26]. As in all population surveys, there may have been a
response bias of which we were not aware. Finally, this
replication was based on American women, as in the
Wichita study, so that these data cannot necessarily be
generalized across other nations or to men.
Conclusion
Implications of this replication
What are the clinical implications of this work? This
study's support for the heterogeneity of CFS, found in an
independent population-derived sample, adds to the
weight of evidence for the heterogeneous nature of CFS.
We do not yet know whether this heterogeneity is impor-
tant in determining response to different treatments, but
future research studies should now examine for modera-
tors of outcome that include obesity, metabolic syn-
drome, sleep problems, depression, and having multiple
symptoms.
As in Wichita, these data suggest that the current research
criteria for CFS, while useful in providing reliable findings
across studies, do not constitute a homogeneous group of
patients. The broadening of the concept of CFS to include
patients with fewer symptoms but similar disability is
supported by this replication [6,7].
What are the research implications of this work? Future
etiological work needs to take into account the heteroge-
neity of CFS, using the determining variables, such as
obesity, multiple symptoms, and depression, to stratify
samples. For instance, obesity leads to fatigue in multiple
ways, including sleep disturbance, metabolic strain,
increased inflammatory markers, and deconditioning
[12,27,28]. This heterogeneity may well explain the
dearth of replicated etiological findings in CFS. Address-
ing heterogeneity up front may help to determine the dif-
ferent etiologies and pathophysiologies that likely
determine the different illnesses that make up CFS.
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